At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Nov 11, 2026 at 16:05 ET
SpyGlass Pharma reported Q3 2026 net loss of $24.3M ($0.73 per share), wider than the $9.8M loss in Q3 2025, driven by higher R&D and G&A expenses. The company highlighted Phase 3 enrollment on track for its BIM-IOL System, four-year FIH efficacy data, and the acquisition of AVS for $13M. Cash of $215.8M is expected to fund operations through 2028.
- Net loss of $24.3M ($0.73 per share) for Q3 2026 vs $9.8M ($4.53 per share) in Q3 2025
- Cash, cash equivalents and short-term investments of $215.8M as of September 30, 2026
- Acquired AVS for ~$13M in cash to secure commercial IOL manufacturing capacity
- Phase 3 enrollment for BIM-IOL System on track, completion expected in 2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access